Big Pharma next generation go-to-market

The pace and urgency of modern life are undoubtedly speeding up, accelerating the accountability of pharmaceutical companies to reshape their relationship with the world.

Now is the time for the industry to facilitate a new go-to-market (GTM) model based on deep engagement with broad coalitions of stakeholders that can supercharge efforts to combat all urgent public health challenges and revitalize disease ecosystems.